Omnicell, Inc. (OMCL) · Oct 29, 2026 · Earnings
Beat — Non-GAAP EPS $0.58 vs ~$0.42 consensus
Omnicell earnings beat Q3 revenue and EPS expectations, lifting EBITDA and EPS guidance while narrowing its 2026 revenue outlook.
Omnicell is moving from business stabilization into a product-refresh cycle built around Titan XT hardware and OmniSphere cloud software, with booking timing still a key execution variable. This quarter strengthens the operating case, but it does not remove the top-line uncertainty.
The quarter beat the market clearly on profitability. Revenue reached $307.9 million, above the published consensus of roughly $304.4 million, while non-GAAP diluted EPS was $0.58 versus approximately $0.42 expected. The beat also cleared Omnicell’s own Q3 revenue, EBITDA and EPS guidance ranges, with revenue and profitability above the high end of prior guidance. 〔0〕
| Metric | Q3 2026 | Q3 comparison | FY26 current | FY26 prior |
|---|---|---|---|---|
| Total revenue (Financial Statements) | $307.9M | $304.4M consensus | $1.225B-$1.231B | $1.225B-$1.245B |
| Non-GAAP diluted EPS (EPS Reconciliation) | $0.58 | ~$0.42 consensus | $2.48-$2.56 | $2.15-$2.30 |
| Non-GAAP EBITDA (EBITDA Reconciliation) | $44.9M | $32M-$37M prior guide | $187M-$193M | $175M-$185M |
| Product revenue (Financial Statements) | $173.1M | $177.5M prior year | $684M-$687M | $690M-$700M |
| Service revenue (Financial Statements) | $134.8M | $133.1M prior year | $541M-$544M | $535M-$545M |
| Annual recurring revenue (2026 Guidance) | $660M-$670M | $660M-$680M |
The quality of the beat is margin-led rather than demand-led. Total revenue declined 0.9% year over year, and product revenue fell 2.5%, but service revenue grew 1.3%; gross margin improved to 44.8% from 43.3%, while non-GAAP EBITDA margin rose to 14.6% from 13.2%. The filing attributes the result to product and service margins and cost discipline, and the numbers support that framing. 〔1〕
Management raised the profit outlook, but trimmed the revenue ceiling. Full-year non-GAAP EBITDA guidance moved to $187 million-$193 million from $175 million-$185 million, and EPS guidance rose to $2.48-$2.56 from $2.15-$2.30. However, the total revenue range narrowed downward at the high end, product revenue guidance fell below the prior range, and ARR’s high end dropped from $680 million to $670 million. 〔2〕
That split matters for the Titan XT and OmniSphere story. The business is demonstrating better conversion of revenue into profit, but the lower product and ARR ceilings suggest the next-generation platform’s growth contribution is not yet translating into a higher near-term sales outlook. Omnicell says customers are validating the combined platform, but the filing provides no bookings increase; product bookings guidance is merely reiterated. 〔3〕 〔4〕
Bottom line: This is a genuine earnings beat with a meaningful profitability upgrade, but not a clean growth reacceleration. Omnicell’s execution is improving faster than its top-line outlook, leaving the business story constructive but still dependent on product bookings and platform adoption converting into revenue.
Q4 results and full-year 2027 outlook
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!